Stockreport

FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF KEYTRUDA Now Approved for First-Line Treatment of Patients with Stage III NSCLC Who Are Not Candidates for Surgical Resection or Definitive Chemoradiatio [Read more]